Fulgent Genetics (FLGT) Payables (2015 - 2026)

Fulgent Genetics has reported Payables for 12 years, with the latest figure at $16.0 million in Q2 2026.

• Quarterly Payables fell 17.18% year-over-year to $16.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $16.0 million (down 17.18% YoY) and the FY2025 annual result came in at $19.1 million, up 1.89% from the prior year.
• Payables slipped to $16.0 million in Q2 2026 per FLGT's latest filing, from $21.6 million in the prior quarter.
• Over five years, Payables peaked at $42.9 million in Q2 2022 and troughed at $16.0 million in Q2 2026.
• A 5-year average of $22.3 million and a median of $20.0 million in 2022 frame the typical range for Payables.
• The sharpest annual moves came in 2022 and 2023: Payables soared 191.0% in 2022, then slumped 42.42% in 2023.
• Over 5 years, Payables stood at $28.7 million in 2022, then plunged by 42.42% to $16.5 million in 2023, then increased by 13.5% to $18.8 million in 2024, then advanced by 1.89% to $19.1 million in 2025, then fell by 16.17% to $16.0 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $16.0 million, $21.6 million, and $19.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.